History
| February 1999 | Established D.Western Therapeutics Institute, Inc. in Nagoya, Aichi Prefecture for the purpose of conducting pharmaceutical research and development (five million yen capitalization) |
|---|---|
| September 2002 | Signed a development and implementation agreement with Kowa Co., Ltd. for K-115, a drug for treating glaucoma |
| November 2004 | Changed from a limited company to a joint-stock corporation (10 million yen capitalization) |
| December 2006 | Entered into an industry-academia-government collaboration agreement with Mie University Faculty of Medicine for joint research, and jointly established Institute of Human Research Promotion and Drug Development at the University |
| October 2009 | Listed on JASDAQ Securities Exchange NEO Market (now Tokyo Stock Exchange Growth market) |
| December 2014 | GLANATEC® ophthalmic solution 0.4% (generic name: Ripasudil hydrochloride hydrate, K-115) for glaucoma launched in Japan |
| June 2015 | Signed an in-licensing agreement to acquire exclusive Japan license for an ophthalmic drug (DW-1001) |
| November 2015 | Made Japan Innovative Therapeutics Inc. a consolidated subsidiary |
| April 2017 | Received transfer of business related to an ophthalmic surgical adjuvant (DW-1002) |
| March 2018 | Initiatied Phase I/IIa clinical trials of glaucoma treatment (H-1337), DWTI’s first in-house developed product, in the U.S. |
| August 2018 | Signed a joint research and licensing agreement with U.S.-based Glaukos Corporation for glaucoma drugs |
| September 2018 | Phase I/IIa clinical trials of H-1337 glaucoma treatment completed in the U.S. |
| August 2019 | Submitted an Investigational New Drug (IND) application for Phase II clinical trials in the U.S. of Ripasudil hydrochloride hydrate as treatment for Fuchs endothelial corneal dystrophy (K-321) |
| December 2019 | Signed an agreement with Rohto Pharmaceutical Co., Ltd., granting exclusive Japan license for ophthalmic drug DW-1001 |
| February 2020 | Phase III clinical trials began in Japan for a fixed combination drug for treating glaucoma (Ripasudil hydrochloride hydrate and Brimonidine tartrate [K-232]) |
| April 2020 | Ophthalmic surgical adjuvant DW-1002 (TissueBlue™) launched in the U.S. |
| August 2020 | Signed a joint development agreement with MEDRx Co., Ltd. for DW-5LBT neuropathic pain treatment |
| August 2020 | Applied for approval of DW-5LBT neuropathic pain treatment in the U.S. |
| September 2020 | Added new disease types (corneal and retinal disorders) for joint research with U.S.-based Glaukos, and signed a new licensing agreement |
| October 2021 | Ophthalmic surgical adjuvant DW-1002 (TissueBlue™) launched in Canada |
| November 2021 | Applied for approval of K-232 glaucoma and ocular hypertension in Japan |
| March 2022 | Phase I clinical trials of DW-1001 began in Japan |
| June 2022 | Signed a joint development agreement with ActualEyes Inc. for DWR-2206 regenerative cell therapy for bullous keratopathy |
| August 2022 | Phase III clinical trials of K-321 for Fuchs endothelial corneal dystrophy began in U.S. |
| December 2022 | GLA-ALPHA® combination ophthalmic solution (generic name: Ripasudil hydrochloride hydrate, brimonidine tartrate, K-232) for glaucoma and ocular hypertension launched in Japan Initiatied Phase IIb clinical trials of glaucoma treatment (H-1337) |